New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 7, 2013
18:07 EDTAMGN, CVS, VZSEC probes Ernst & Young on lobbying issue, Reuters says
The SEC's enforcement division and its Office of the Chief Accountant are looking in to a report that Washington Council Ernst & Young was registered as a lobbyist for several corporate audit clients including Amgen (AMGN), CVS Caremark (CVS) and Verizon Communications (VZ), says Reuters, citing people familiar with the matter. Reference Link
News For AMGN;CVS;VZ From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
October 20, 2014
15:36 EDTVZNotable companies reporting before tomorrow's open
Subscribe for More Information
15:19 EDTVZVerizon technical commentary before earnings
Subscribe for More Information
13:53 EDTVZEarnings Preview: Verizon sentiment mixed ahead of Q3 report
Subscribe for More Information
07:19 EDTAMGNIBC Life Sciences to hold a conference
Subscribe for More Information
07:17 EDTVZVerizon weekly volatility elevated into Q3 and outlook
Verizon October weekly call option implied volatility is at 25, November and January is at 16; compared to its 26-week average of 15 according to Track Data, suggesting large near term price movement into the expected release of Q3 results on October 21.
October 19, 2014
15:56 EDTAMGNAmgen to aid in production method for Ebola drug ZMapp, Bloomberg says
Subscribe for More Information
October 17, 2014
09:06 EDTAMGNAmgen files patent infringement lawsuit against Sanofi, Regeneron
Amgen (AMGN) announced that it filed a lawsuit in the United States District Court of Delaware against Sanofi (SNY), Aventisub, formerly doing business as Aventis Pharmaceuticals, and Regeneron Pharmaceuticals (REGN) for patent infringement of U.S. Patent Numbers 8,563,698, 8,829,165, and 8,859,741. These patents, which are owned by Amgen, describe and claim monoclonal antibodies to proprotein convertase subtilisin/kexin type 9, or PCSK9. By its complaint, Amgen seeks an injunction to prevent the infringing manufacture, use and sale of Sanofi and Regeneron's alirocumab, a monoclonal antibody targeting PCSK9. Sanofi and Regeneron recently announced that they have completed Phase 3 clinical trials on alirocumab and intend to pursue regulatory approval to market alirocumab in the U.S. Amgen previously announced submission of a Biologics License Application to the FDA for evolocumab, its own investigational human monoclonal antibody to PCSK9, for the treatment of high cholesterol, on Aug. 28.
October 14, 2014
11:23 EDTAMGNBIND Therapeutics and The Conference Forum hold a conference
Subscribe for More Information
09:37 EDTVZActive equity options trading on open
Subscribe for More Information
08:13 EDTVZCorvex says Crown Castle, Verizon deal would 'diversify' revenues
Corvex said, "A Verizon (VZ) tower deal would diversify Crown Castle's (CCI) revenues and deepen the company's relationship with arguably the U.S.'s strongest wireless company and operator of the country's most robust network. As the largest and most-focused U.S. tower operator and the largest operator of legacy carrier portfolios, Crown Castle could be the best strategic acquirer of Verizon's tower assets. That does not mean the company will be best positioned financially to provide the highest and best bid though. Based on recent press articles, the potential sale price for the Verizon towers could be approximately $6B. However, we strongly believe that the company should not issue any equity at recent prices, and certainly not to acquire more tower assets at premium prices when Crown Castle continues to trade at a material discount to both transaction multiples and publicly traded peers."
October 13, 2014
07:39 EDTCVSPharmaceutical Care Management Association to hold annual meeting
Subscribe for More Information
October 9, 2014
16:11 EDTAMGNAmgen blinatumomab granted priority review by FDA
Subscribe for More Information
09:33 EDTVZGE, Verizon announce alliance
Subscribe for More Information
08:32 EDTCVSCVS Health price target raised to $95 from $87 at Leerink
Subscribe for More Information
06:33 EDTCVSCourt considers whether to pay Amazon workers for security checks, WSJ says
Subscribe for More Information
October 8, 2014
10:20 EDTAMGNAmgen biosimilar franchise underappreciated, says Piper Jaffray
After Amgen announced positive Phase 3 results for its biosimilar Humira in psoriasis, Piper Jaffray said it believes that Amgen's overall pipeline is underappreciated since the company's biosimilar franchise is generally not included in consensus estimates. The firm views Amgen as a top large cap picks and reiterate its Overweight rating on the stock.
09:38 EDTVZActive equity options trading on open
Subscribe for More Information
09:16 EDTAMGNAmgen's ABP 501 for psoriasis shows positive Phase 3 results
Subscribe for More Information
07:19 EDTAMGNCBI to hold a conference
Subscribe for More Information
07:11 EDTAMGNEuropean Academy of Dermatology and Venereology to hold a conference
23rd EADV Congress is being held in Amsterdam, The Netherlands on October 8-12.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use